Literature DB >> 31227991

Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis.

Claudio Ricci1,2, Carlo Ingaldi3,4, Laura Alberici3,4, Nicole Brighi4,5, Donatella Santini4,6, Cristina Mosconi4,7, Valentina Ambrosini4,5, Davide Campana3,4, Francesco Minni3,4, Riccardo Casadei3,4.   

Abstract

PURPOSE: The European Neuroendocrine Tumor Society (ENETS) guidelines advocate a right hemicolectomy (RHC) only in patients with appendiceal neuroendocrine neoplasms (aNENs) at risk for N+(node positive). The risk is defined using site, size, and grading of tumor as well as mesoappendiceal or lymphovascular invasion.
METHODS: A systematic review and meta-analysis was carried out. The data were reported using risk difference (RD) to define the risk of N+. The number needed to treat/harm (NNT/NNH) and the likelihood of being helped or harmed (LHH) were calculated using RD. Two strategies were considered: "to treat all" versus "to treat only patients having aNENs with risk stigmata". The aim was to evaluate the harm/benefit ratio related to the use of the ENETS lymph-nodal metastases (N+) risk factors.
RESULTS: Six studies were included involving a total of 261 patients. The RD (-0.30; P < 0.001) of N+ was significantly lower in aNENs ≤ 20 mm as compared to those >20 mm. One unnecessary RHC every five patients (NNT = 5) could be avoided while 1 patient with N+ every six patients (NNH = 6) remained untreated. The risk was lower than the benefits (LHH = 1.2). The RD NNT, NNH, and LHH values suggested that only a 15 mm cutoff and the presence of lymphovascular invasion could be considered useful.
CONCLUSIONS: An RHC should be performed in patients with aNENs >20 mm. The use of a 15 mm cutoff criterion had a similar outcome to that of a 20 mm cutoff. Lymphovascular invasion should only be considered a minor criterion. Selection based on other parameters should be avoided.

Entities:  

Keywords:  Appendix; Carcinoid; Neuroendocrine tumor

Mesh:

Year:  2019        PMID: 31227991     DOI: 10.1007/s12020-019-01984-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  4 in total

Review 1.  Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.

Authors:  José Luis Muñoz de Nova; Jorge Hernando; Miguel Sampedro Núñez; Greissy Tibisay Vázquez Benítez; Eva María Triviño Ibáñez; María Isabel Del Olmo García; Jorge Barriuso; Jaume Capdevila; Elena Martín-Pérez
Journal:  World J Gastroenterol       Date:  2022-04-07       Impact factor: 5.374

2.  The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas; Simona Grozinsky-Glasberg; Kira Oleinikov; Beata Kos-Kudła; Angelika Kogut; Rajaventhan Srirajaskanthan; Michail Pizanias; Kalliopi-Anna Poulia; Clara Ferreira; Martin O Weickert; Kosmas Daskalakis
Journal:  Endocrine       Date:  2020-07-24       Impact factor: 3.633

3.  The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients.

Authors:  Kosmas Daskalakis; Krystallenia Alexandraki; Evanthia Kassi; Marina Tsoli; Anna Angelousi; Athanasia Ragkousi; Gregory Kaltsas
Journal:  Endocrine       Date:  2019-09-06       Impact factor: 3.633

Review 4.  Acute appendicitis-advances and controversies.

Authors:  Thomas Zheng Jie Teng; Xuan Rong Thong; Kai Yuan Lau; Sunder Balasubramaniam; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.